Quantcast
Last updated on April 16, 2014 at 11:13 EDT

Latest Dana-Farber Cancer Institute Stories

2011-07-11 07:00:00

WHITE PLAINS, N.Y., July 11, 2011 /PRNewswire/ -- The Leukemia & Lymphoma Society (LLS) is taking an aggressive and proactive approach to tackling the challenge of improving outcomes for cancer patients with particularly urgent needs. (Logo: http://photos.prnewswire.com/prnh/20110215/NY48642LOGO ) Earlier this year, LLS identified three underdeveloped but promising areas of research and sought proposals to help stimulate more academic research in these areas: the malignant stem...

2011-06-30 13:41:10

Researchers at Dana-Farber Cancer Institute have demonstrated a molecular strategy they say could make a much larger variety of tumors treatable with PARP inhibitors, a promising new class of cancer drugs. Currently, the role of PARP inhibitors has mainly been restricted to cancers whose cells lack functioning versions of the damage-repair proteins BRCA1 or BRCA2 -- chiefly certain breast and ovarian cancers. In a paper published online by Nature Medicine, Geoffrey Shapiro, MD, and colleagues...

2011-06-15 09:07:00

BRAINTREE, Mass., June 15, 2011 /PRNewswire/ -- Herman Lowe, who has been battling terminal brain cancer, Glioblastoma, for over two years, has written a free online book, "Brain Cancer: Beating the Odds" about his journey and what he has done to try to help others with this deadly disease. Lowe, a semi-retired clinical psychologist, explains in the book why he is convinced that the use of cell phones has played a significant role in his contracting brain cancer. While he knows that...

2011-06-09 23:33:23

Blocking cyclin D1 might help sensitize tumors to radiation Scientists at Dana-Farber Cancer Institute have uncovered a new role for a key cancer protein, a finding that could pave the way for more-effective radiation treatment of a variety of tumors. Many cancers are driven in part by elevated levels of cyclin D1, which allow the cells to escape growth controls and proliferate abnormally. In the new research, reported in the June 9 issue of Nature, researchers discovered that cyclin D1 also...

2011-06-09 08:04:00

AMSTERDAM and IRVINE, California, June 9, 2011 /PRNewswire/ -- Agendia, a commercial-stage molecular cancer diagnostics company, announces today that it has entered into a research collaboration with The University of Texas MD Anderson Cancer Center, one of the world's leading cancer centers and whose research program is considered one of the most productive in the world aimed solely at cancer, and the Netherlands Cancer Institute (NKI) with the aim of improving diagnosis and treatment...

2011-06-06 12:56:15

A duo of drugs, each targeting a prime survival strategy of tumors, can be safely administered and are potentially more effective than either drug alone for advanced, inoperable melanomas, according to a phase 1 clinical trial led by Dana-Farber Cancer Institute investigators. The findings (abstract 8511), will be presented in an oral session at the annual meeting of the American Society of Clinical Oncology on Saturday, June 4, 3 p.m. CT, Arie Crown Theater, McCormick Place. The drugs --...

2011-06-06 07:59:23

(Ivanhoe Newswire) -- Scientists have identified an overactive network of genes that drive certain cancer cells enriched in triple-negative breast tumors. Triple-negative breast cancers are characterized by a lack of estrogen, progesterone and HER2 receptors, which makes them unresponsive to targeted treatments that block those receptors. These tumors make up about 15 to 20 percent of breast cancers and tend to occur in younger women, those with BRCA1 gene mutations and black women....

2011-06-01 23:01:18

Potential new drug target for hard-to-treat 'triple-negative' tumors Scientists at Dana-Farber Cancer Institute have identified an overactive network of growth-spurring genes that drive stem-like breast cancer cells enriched in triple-negative breast tumors, a typically aggressive cancer that is highly resistant to current therapies. Kornelia Polyak, MD, PhD, a breast cancer geneticist at Dana-Farber, and colleagues found that a large proportion of cells within these tumors showed elevated...

2011-06-01 00:06:40

One of the largest pediatric cancer centers in the U.S. advances research in neuroblastoma Philadelphia, PA (PRWEB) May 31, 2011 Cookies for Kids' Cancer, a nonprofit foundation dedicated to raising funds and awareness for pediatric cancer research, has awarded $200,000 in grants to the Cancer Center at The Children's Hospital of Philadelphia, one of the largest pediatric cancer centers in the United States, and home to the Center for Childhood Cancer Research. "Physician-scientists within...

2011-05-31 08:21:00

PHILADELPHIA, May 31, 2011 /PRNewswire-USNewswire/ -- Cookies for Kids' Cancer, a nonprofit foundation dedicated to raising funds and awareness for pediatric cancer research, has awarded $200,000 in grants to the Cancer Center at The Children's Hospital of Philadelphia, one of the largest pediatric cancer centers in the United States, and home to the Center for Childhood Cancer Research. "Physician-scientists within the Center for Childhood Cancer Research at The Children's Hospital of...